Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver

Positive

AI Analysis

Summary

Evonik is expanding its lipid-based drug delivery capabilities by opening a new GMP manufacturing facility in Vancouver, investing over 150 million CAD with up to 68 million CAD in external funding support to meet growing demand for LNP development and clinical manufacturing.

Importance:4/10

Sentiment:

0.60

lipid nanoparticlesLNPmanufacturingGMP facilitydrug deliveryinfrastructureVancouver

Read the original article

Published by PR Newswire Biotech on August 27, 2026 7:17 PM

Read Original